ClearPoint Neuro将于2025年11月和12月出席三次保健投资者会议,展示其经林业发展局清理的大脑和脊椎导航系统在全球使用。 ClearPoint Neuro will present at three healthcare investor conferences in November and December 2025, showcasing its FDA-cleared brain and spine navigation system used globally.

ClearPoint Neuro公司将在2025年底出席三次主要的保健投资者会议:11月10日的UBS全球保健会议、11月13日的Stifel保健会议以及12月3日的Piper Sandler保健会议。 ClearPoint Neuro, Inc. (CLPT) will present at three major healthcare investor conferences in late 2025: the UBS Global Healthcare Conference on November 10, the Stifel Healthcare Conference on November 13, and the Piper Sandler Healthcare Conference on December 3. 公司行政主管将亲自会见投资者。 Company executives will meet with investors in person. 该公司经FDA批准和CE标记的导航系统支持全球数以千计的大脑和脊椎程序,能够准确提供细胞和基因疗法。 The firm’s FDA-cleared and CE-marked navigation system supports thousands of brain and spine procedures globally and enables precise delivery of cell and gene therapies. 它服务于多个大陆的医疗保健提供者、研究机构和生物制药伙伴。 It serves healthcare providers, research institutions, and biopharmaceutical partners across multiple continents. 前瞻性说明包括对增长、收入和筹资的预期,但须视监管、经济和竞争风险而定。 Forward-looking statements include expectations for growth, revenue, and funding, subject to regulatory, economic, and competitive risks.